Humana Has Beat Estimates Three Times Running While Its Stock Refuses to Follow

Humana Inc. (HUM) reports second-quarter earnings before the market opens on July 29, 2026, with analysts expecting $6.22 per share — a sharp decline from the prior year's $6.27. The central question: can the Medicare Advantage giant stabilize profitability after a volatile year that saw a $3.96 loss in Q4 2025, or will mounting pressures in its core business drive another disappointing quarter?

Part 1: Earnings Preview

Humana Inc. is one of the nation's largest health insurance providers, specializing in Medicare Advantage plans, prescription drug coverage, and other healthcare services for seniors and government-sponsored beneficiaries. The company's performance is closely tied to medical cost trends, government reimbursement rates, and enrollment dynamics in its Medicare Advantage business.

Humana is scheduled to report second-quarter results before the market opens on July 29, 2026. The consensus estimate stands at $6.22 per share from 9 analysts, with a wide range spanning from $1.61 to $7.94. The company most recently reported $10.31 per share for Q1 2026, beating estimates by 3.41%. Year-over-year, the Q2 2026 estimate of $6.22 represents a 0.80% decline from the $6.27 reported in Q2 2025, signaling continued pressure on profitability.

Three key themes define this earnings story:

Medicare Advantage Margin Pressure: Humana's core Medicare Advantage business has faced persistent headwinds from elevated medical costs and unfavorable government reimbursement adjustments. Investors will scrutinize medical loss ratios and commentary on whether cost trends are stabilizing or continuing to erode margins.

Enrollment Growth vs. Profitability Trade-off: The company has historically prioritized membership growth, but the question now is whether Humana can balance enrollment gains with profitable underwriting. Any guidance on member retention and the quality of new enrollments will be critical.

Full-Year Outlook Reset: After a disastrous Q4 2025 loss of $3.96 per share, analysts have slashed full-year 2026 estimates to just $9.46 — down from prior expectations of $17.14. Management's updated guidance and confidence in achieving even these reduced targets will be a focal point.

Analyst commentary ahead of the release reflects cautious optimism tempered by structural concerns. While some analysts point to potential stabilization in medical costs and improved pricing discipline, others remain skeptical about Humana's ability to return to consistent profitability given ongoing industry headwinds and regulatory uncertainty.

Part 2: Historical Earnings Performance

Humana's recent earnings history reveals a pattern of modest beats and misses, but with significant volatility in absolute results. Over the past four quarters, the company has delivered two beats and two misses against consensus estimates, with surprise magnitudes ranging from -0.79% to +11.34%.

The most striking feature is the dramatic swing in reported earnings: Q2 2025 delivered $6.27, Q3 2025 came in at $3.24 (beating by 11.34%), Q4 2025 posted a shocking loss of $3.96, and Q1 2026 rebounded strongly to $10.31 (beating by 3.41%). This volatility reflects the company's struggle with medical cost management and seasonal patterns in its Medicare business.

The trend suggests Humana is capable of exceeding lowered expectations — three of the past four quarters saw beats or near-misses — but the underlying earnings power remains deeply uncertain. The Q4 loss was a watershed moment that reset investor expectations, and the Q1 rebound, while encouraging, leaves questions about sustainability heading into Q2.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Humana typically reports earnings before the market opens, meaning Day 0 captures the first full trading session reaction to results, while Day +1 reflects follow-through momentum.

Humana's stock exhibits significant volatility around earnings, with an average absolute Day 0 move of 5.76% and an average intraday range of 8.44%. The most recent report on April 29, 2026, saw the stock surge 5.83% on Day 0 with a 13.34% intraday range, followed by a 2.75% decline on Day +1.

Historical patterns show wide dispersion: the stock has moved as much as 12.40% higher (July 2025) and 10.61% lower (July 2024) on earnings day. Day +1 follow-through averages 2.71% in absolute terms, suggesting initial reactions often moderate but can extend in either direction. Investors should prepare for substantial price swings, particularly given the current uncertainty around profitability trends and guidance.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 7.94% (±$30.87) for this week's expiration, which is above the historical average Day 0 move of 5.76% but below the average intraday range of 8.44%. This suggests options traders are anticipating elevated volatility consistent with recent earnings reactions, though not an outlier event.

Part 3: What Analysts Are Saying

Analysts maintain a cautiously optimistic stance on Humana heading into earnings. The current consensus rating stands at 3.58 (between Hold and Buy) with an average price target of $353.54, implying 9.05% downside from the current price of $388.71. The target range is exceptionally wide, spanning from $195.00 to $502.00, reflecting deep disagreement about the company's trajectory.

The analyst community is split: 9 Strong Buys and 1 Moderate Buy are offset by 14 Holds and 2 Strong Sells among 26 total recommendations. Notably, sentiment has improved over the past month, with one analyst upgrading from Hold to Strong Buy, suggesting some growing confidence in stabilization.

However, the consensus price target of $353.54 sits 9.05% below the current stock price, indicating that even bullish analysts see limited near-term upside until the company demonstrates sustained earnings recovery. The wide dispersion in targets — from $195 to $502 — underscores the binary nature of the investment case: either Humana successfully navigates its margin challenges and the stock has significant upside, or profitability pressures persist and further downside looms.

Part 4: Technical Picture

Humana's technical setup heading into earnings shows a stock that has rallied strongly off its lows but is now consolidating just below recent peaks. The Barchart Technical Opinion currently registers 80% Buy, down from 100% Buy one week ago and 88% Buy one month ago, indicating some near-term momentum loss despite the overall positive signal.

Timeframe Analysis:

• Short-term (50% Buy): Moderate buy signal suggests near-term momentum has cooled after the recent rally, with the stock pulling back slightly from recent highs
• Medium-term (100% Buy): Strong buy signal indicates solid intermediate-term uptrend remains intact as the stock holds well above its 50-day moving average
• Long-term (100% Buy): Strong buy signal reflects the powerful recovery trend from earlier lows, with the stock trading well above all major long-term moving averages

The trend characteristics show Strong strength with Average direction, suggesting a well-established uptrend that has paused but not reversed heading into the earnings event.

The stock is trading at $388.71, positioned below its 5-day ($390.26), 10-day ($394.81), and 20-day ($396.90) moving averages, indicating recent short-term weakness. However, it remains well above its 50-day ($364.16), 100-day ($284.53), and 200-day ($263.99) moving averages, confirming the longer-term uptrend is intact. The recent pullback from the $396-$397 area may provide a more favorable entry point for bulls, though the proximity to short-term resistance suggests limited cushion if results disappoint.

Key resistance now sits at the 20-day moving average around $397, while support appears at the 50-day moving average near $364. The technical setup is moderately supportive — the stock has room to run if earnings surprise positively, but the recent loss of short-term momentum and position below near-term moving averages suggests vulnerability to downside if results or guidance disappoint. The strong longer-term trend provides a foundation, but traders should be prepared for the 7.94% expected move in either direction.